The Swiss company Curatis and the Japanese pharmaceutical company Neupharma have signed an exclusive license agreement to develop and commercialize the drug corticorelin (C-PTBE-01) in Japan.[1] The drug is indicated for the treatment of peritumoral brain edema (PTBE), a tumor-associated condition for which there are currently no approved targeted therapies.[1] Neupharma will fund and conduct the pivotal clinical trial in Japan required to obtain regulatory approval.[1] Curatis will be entitled to an initial payment and additional payments for achieving regulatory and commercial targets of up to 83.5 million Swiss francs, as well as royalties on future sales in Japan of up to 20 percent.[1] The drug will initially be targeted at children and adolescents, with a meeting with Japan's PMDA regulatory body scheduled for summer 2026 and a clinical trial expected to begin in 2027.[1] At the same time, Curatis continues preparatory work on the pivotal phase 3 study required for approval in the US and Europe.[1]